hotspot -WSS

hotspot

author：hotspot 2025-09-28 19:25:50 - browse：827

Verve Therapeutics CEO Sekar Kathiresan Verve

SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines for rare, life-threatening diseases that generally affect small numbers of patients. But since Verve Therapeutics was founded in 2018, it’s had a wider aperture: using the molecular tools of genome editing to go after the most common cause of death in the world.

The plan, according to Verve CEO Sekar Kathiresan, is to edit out heart attacks for the millions of people at risk for severe cardiovascular disease. It’s a goal that’s more than a little audacious. There’s just one approved genome editing medicine, a treatment for sickle cell disease, and it only passed Food and Drug Administration review last month. Base editing, the CRISPR successor Verve uses to conduct its molecular surgery, is only a few years old.

“When we started, there were so many things that we were kind of going against the grain on,” Kathiresan told STAT at the J.P. Morgan Healthcare Conference in San Francisco this week. “In 2018, it was all about platforms, not about specific diseases and products, or taking this kind of idea for a large indication as opposed to cancer or rare disease. But we’ve always been motivated by a deep conviction in one simple research insight, which is that if your blood cholesterol is really low, lifelong, it is very hard to get a heart attack.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Kidney transplant patients stopped immunosuppressants in trial

WSS

FDA rejects Alnylam's heart disease treatment over insufficient data

Why age limits for politicians are a terrible idea

Medicare proceeds with plan to claw back hospital funds

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Medicare proceeds with plan to claw back hospital funds

Prime Medicine says its gene editing passes test in monkeys

hotspot

hotspot

hotspot

Medical leaders decry Supreme Court decision on affirmative action

FDA authorizes Novavax’s updated Covid

Apple is now the first public company to be valued at $3 trillion

The future of health care in the House

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Liquid biopsy for lung cancer is launched by Delfi

The cancer drug shortage isn’t new — and neither are the solutions

When women are denied an abortion, their children fare worse than peers

Psychedelics group wrestles with new pharma identity

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Wikipedia

Colorectal cancer study finds potential in overlooked immune cell

Senate panel eyes new effort on drug shortages

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

AI can decode, harness the power of the humane immune system

Live blog: Hearing on CRISPR

Wikipedia

entertainment

hotspot

Wikipedia